Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Preclinical data on prodrug for ovarian cancer presented at cancer meeting
May 19th, 2005
Telik, Inc. (TELK) reported new preclinical data that support the company's ongoing Telcyta (TLK286) clinical development program. The data were reported at the 96th Annual Meeting of the American Association for Cancer Research. Telik scientists reported that TELCYTA was not cross-resistant with carboplatin in carboplatin resistant ovarian cancer cells and that the combination of Telcyta and carboplatin showed synergistic inhibition as measured by the combination index method in both platinum resistant as well as platinum sensitive ovarian cancer cells. These studies support the ongoing phase 3 ASSIST-3 registration trial, in which the combination of Telcyta and...
Source: Women's Health Weekly (2005-05-19)
|
